|
**Overview**: **Cancer Breast Comprehensive Profile****Introduction**: The Cancer Breast Comprehensive Profile is a diagnostic tool designed to conduct breast cancer screening and monitoring using serum samples. Associated with conditions like invasive ductal carcinoma and metastatic breast cancer, these disorders present with lumps, pain, and severe complications if untreated, particularly in individuals with breast cancer risk. Per the 2023 Oncology guidelines, the test employs biochemistry with immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for cancer screening in clinical settings. This diagnostic falls under cancer screening and targets individuals with suspected or confirmed breast cancer, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Breast Cancer Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by oncology labs, this test advanced breast cancer diagnostics.**Purpose**: The test screens for 10 parameters including CA 15-3 to guide breast cancer assessment, assess tumor markers, and inform treatment and prevention strategies.**Test Parameters**: 1. CA 15-3, 2. CEA, 3. CA 125, 4. AFP, 5. Beta-hCG, 6. CA 19-9, 7. Total PSA (for metastasis), 8. Free PSA, 9. BRCA1, 10. BRCA2.**Pretest Condition**: No fasting required; patients should report lumps, pain, or recent breast changes.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on lumps, pain, prior cancer reactions, or family history of breast cancer, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated breast cancer including metastasis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent surgery can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible breast cancer, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early disease stages.**Specialist Consultation**: General practitioners or specialists in oncology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Mammography or biopsy for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in benign conditions, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Oncology Guidelines 2023, Journal of Breast Cancer 2024, Biochemistry 2025. |
